Long-term impact of ixekizumab on psoriasis itch severity : Results from a phase III clinical trial and long-term extension
Kimball, Alexandra B. (Harvard Medical School)
Luger, Thomas (University of Muenster)
Gottlieb, Alice (New York Medical College)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Kaufmann, Roland (Goethe University)
Burge, Russel (University of Cincinnati)
Lin, Chen-Yen (Eli Lilly and Company)
Yosipovitch, Gil (University of Miami Miller School Of Medicine)
Universitat Autònoma de Barcelona

Date:	2018
Abstract:	Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance therapy (80-mg ixekizumab every 4 weeks [IXEQ4W]) on itch severity, using the Itch Numeric Rating Scale, in psoriasis patients who received ixekizumab, placebo, or etanercept for 12 weeks in the Phase III UNCOVER-3 trial. After 12 weeks, patients either continued or switched to IXEQ4W. Mean improvements in itch severity achieved with 12 weeks of ixekizumab (-4. 7 to -5. 1) were maintained through 60 weeks with IXEQ4W (-4. 9 to -5. 0). Patients who initially received placebo or etanercept experienced rapid itch severity improvements after switching to ixekizumab at Week 12 (Week 12, placebo: -0. 6; etanercept: -3. 8; Week 60, placebo/IX-EQ4W: -4. 9; etanercept/IXEQ4W: -4. 7). Ixekizumab maintenance therapy sustained improvements in itch severity through 60 weeks.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Itch ; Itch NRS ; Ixekizumab ; Psoriasis ; Maintenance ; Long-term outcomes
Published in:	Acta dermato-venereologica, Vol. 98 Núm. 1 (2018) , p. 98-102, ISSN 1651-2057

DOI: 10.2340/00015555-2801
PMID: 28929168

5 p, 414.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles